Cover Image
市場調查報告書

腎臟癌:開發平台分析

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229726
出版日期 內容資訊 英文 1113 Pages
訂單完成後即時交付
價格
Back to Top
腎臟癌:開發平台分析 Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 1113 Pages
簡介

腎臟癌,是腎臟細胞惡性化變成癌症,產生不能控制的腫瘤的疾病。症狀上有血尿、食慾不振、持續數週發燒、強烈疲勞感、貧血、呼吸急促、骨痛等。治療方法有外科手術、放射治療、化療等。

本報告提供腎臟癌的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 腎臟癌 概要

治療藥的開發

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8816IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 73, 71, 4, 65, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 6, 9 and 1 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Kidney Cancer (Renal Cell Cancer) Overview
  • Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes
  • Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance
  • Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies
  • Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes
  • Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment
  • Drug Profiles
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products
  • Kidney Cancer (Renal Cell Cancer) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016
  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Acceleron Pharma Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aduro BioTech Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aphios Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aravive Biologics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ARMO Biosciences Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ATLAB Pharma SAS, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by BeiGene Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Biocad, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellceutix Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cleave Biosciences Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by COARE Biotechnology Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Corcept Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cytune Pharma SAS, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by EirGenix Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by HEC Pharm Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Hemispherx Biopharma Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immatics Biotechnologies GmbH, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Incuron LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Inspyr Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Intech Biopharm Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MediaPharma srl, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Medivation Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Moleculin Biotech Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corp, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoTherapy Science Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharma Mar SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmacyclics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio SL, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Richter Gedeon Nyrt, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Theravectys SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vyriad Inc, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..1), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..2), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..3), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..4), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..5), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..6), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..7), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..8), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..9), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..10), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..11), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..12), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..13), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..14), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..15), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..16), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..17), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..18), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..19), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..20), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..21), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..22), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..23), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..1), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..2), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..3), H2 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..4), H2 2016

List of Figures

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016
  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top